Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor, commonly abbreviated as NDRI. It belongs to the aminoketone chemical class, which makes it structurally and functionally distinct from the more commonly prescribed SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors). It is also classified broadly as an antidepressant and, under the brand name Zyban, as a smoking cessation aid.
How Bupropion Works in the Brain
Most antidepressants target serotonin, either alone or in combination with other brain chemicals. Bupropion takes a different approach. It blocks the reabsorption of two neurotransmitters, dopamine and norepinephrine, allowing more of each to remain active in the spaces between nerve cells. This is what makes it an NDRI rather than an SSRI or SNRI.
Bupropion has slightly stronger effects on dopamine transporters than on norepinephrine transporters, and its impact on serotonin is essentially zero. It also doesn’t bind to histamine, acetylcholine, or adrenergic receptors, which is why it avoids many of the side effects tied to other antidepressant classes. After you take it, your body converts it into several active metabolites, the most important being hydroxybupropion, which continues the same reuptake-blocking activity. Both bupropion and hydroxybupropion have elimination half-lives of roughly 20 to 21 hours with regular dosing.
Why Its Class Matters for Side Effects
The reason many people end up searching for bupropion’s drug class is that it behaves so differently from other antidepressants. Because it doesn’t touch serotonin, it largely sidesteps three of the most common complaints about SSRIs: sexual dysfunction, weight gain, and sedation.
Sexual dysfunction affects an estimated 58% to 73% of men taking SSRIs. In pooled comparison trials, bupropion caused significantly less sexual desire disorder, arousal disorder, and difficulty with orgasm. In fact, the rate of sexual side effects during bupropion therapy was virtually identical to placebo. Some clinicians add bupropion alongside an SSRI specifically to counteract SSRI-induced sexual dysfunction, and randomized trial data supports that this approach can be effective.
Bupropion is also weight-neutral or mildly associated with weight loss, which contrasts with the weight gain many people experience on serotonin-targeting antidepressants.
FDA-Approved Uses
Bupropion carries three FDA-approved indications:
- Major depressive disorder in adults, marketed as Wellbutrin (IR, SR, and XL formulations)
- Seasonal affective disorder, also under the Wellbutrin XL brand
- Smoking cessation, marketed as Zyban
It is also used off-label for ADHD in adults, particularly when standard ADHD medications aren’t appropriate. A Cochrane review of the evidence found that bupropion modestly reduced ADHD symptom severity and increased the proportion of adults who experienced meaningful clinical improvement compared to placebo, though the overall evidence quality was rated low.
Available Formulations
Bupropion comes in three release profiles, all bioequivalent but dosed differently throughout the day:
- Immediate release (IR), taken three times daily
- Sustained release (SR), taken twice daily, introduced in 1996
- Extended release (XL), taken once daily, introduced in 2003
For depression, the typical starting dose is 150 mg per day, with a maximum of 300 mg per day for the XL formulation. Some prescribers increase the dose as early as one week after starting, depending on the response.
Seizure Risk and Contraindications
The most important safety consideration with bupropion is seizure risk, which is dose-dependent. At the recommended maximum of 450 mg per day or less, the incidence of seizures ranges from 0.35% to 0.44%, with a cumulative two-year risk of about 0.48%. The risk climbs meaningfully above 450 mg per day, and more than half of reported seizure cases involved predisposing factors.
Because of this risk, bupropion is contraindicated in people with seizure disorders and in those with a current or prior diagnosis of bulimia or anorexia nervosa, since eating disorders are associated with a higher seizure incidence during treatment. Other contraindications include severe head injury, brain tumors, and abrupt withdrawal from alcohol, benzodiazepines, or barbiturates, all of which independently lower the seizure threshold.
How It Compares to Other Antidepressant Classes
If you’re trying to place bupropion in the broader landscape of antidepressants, it helps to know the main categories. SSRIs (like sertraline and fluoxetine) boost serotonin. SNRIs (like venlafaxine and duloxetine) boost both serotonin and norepinephrine. Tricyclics affect multiple neurotransmitter systems and carry more side effects. Bupropion stands alone as the only widely prescribed NDRI, acting on dopamine and norepinephrine while leaving serotonin untouched.
This unique profile makes it a common choice when someone hasn’t responded well to SSRIs, can’t tolerate serotonin-related side effects, or needs an antidepressant that doesn’t cause weight gain or sexual problems. It’s also frequently combined with an SSRI to broaden coverage across neurotransmitter systems.